1. Home
  2. ENTO vs NCPL Comparison

ENTO vs NCPL Comparison

Compare ENTO & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • NCPL
  • Stock Information
  • Founded
  • ENTO 2014
  • NCPL 1984
  • Country
  • ENTO United States
  • NCPL United States
  • Employees
  • ENTO N/A
  • NCPL N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • NCPL Investment Managers
  • Sector
  • ENTO Health Care
  • NCPL Finance
  • Exchange
  • ENTO Nasdaq
  • NCPL Nasdaq
  • Market Cap
  • ENTO 1.2M
  • NCPL 1.2M
  • IPO Year
  • ENTO 2016
  • NCPL N/A
  • Fundamental
  • Price
  • ENTO $0.62
  • NCPL $1.57
  • Analyst Decision
  • ENTO
  • NCPL
  • Analyst Count
  • ENTO 0
  • NCPL 0
  • Target Price
  • ENTO N/A
  • NCPL N/A
  • AVG Volume (30 Days)
  • ENTO 924.5K
  • NCPL 428.3K
  • Earning Date
  • ENTO 10-21-2024
  • NCPL 12-12-2024
  • Dividend Yield
  • ENTO N/A
  • NCPL N/A
  • EPS Growth
  • ENTO N/A
  • NCPL N/A
  • EPS
  • ENTO N/A
  • NCPL N/A
  • Revenue
  • ENTO N/A
  • NCPL $3,573,853.00
  • Revenue This Year
  • ENTO N/A
  • NCPL $71.18
  • Revenue Next Year
  • ENTO N/A
  • NCPL $34.07
  • P/E Ratio
  • ENTO N/A
  • NCPL N/A
  • Revenue Growth
  • ENTO N/A
  • NCPL N/A
  • 52 Week Low
  • ENTO $0.19
  • NCPL $1.41
  • 52 Week High
  • ENTO $14.51
  • NCPL $47.60
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 59.35
  • NCPL 38.03
  • Support Level
  • ENTO $0.38
  • NCPL $1.42
  • Resistance Level
  • ENTO $0.87
  • NCPL $1.90
  • Average True Range (ATR)
  • ENTO 0.14
  • NCPL 0.17
  • MACD
  • ENTO 0.03
  • NCPL 0.07
  • Stochastic Oscillator
  • ENTO 52.57
  • NCPL 32.65

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

Share on Social Networks: